Core Viewpoint - The article highlights the investment in Sichuan Yingjiaohesheng Technology Co., Ltd., a major producer of steviol glycosides, emphasizing its innovative approach using synthetic biology and its significant market potential in the sugar substitute industry [5][8]. Group 1: Company Overview - Yingjiaohesheng was established in 2015 and focuses on producing natural products using synthetic biology technology, with applications in pharmaceuticals, health supplements, and food and beverages [8]. - The company is recognized as one of the largest suppliers of steviol glycosides in China and has successfully entered the U.S. market since 2019, becoming part of the global supply chains of several international food and beverage companies [8][10]. - Yingjiaohesheng's product line includes coenzyme Q10, new steviol glycosides, β-nicotinamide mononucleotide (NMN), and vanillin, covering multiple sectors [8]. Group 2: Market and Technology - Steviol glycosides are a key component in many "zero-calorie" food and beverage products, with a caloric value only 1/300 that of sucrose, making them a popular sugar substitute [6][8]. - The company’s unique technology route—synthetic biology—offers significant cost advantages over traditional extraction methods, which have low yield and high waste [10]. - Synthetic biology allows for the production of steviol glycosides at a scale that can surpass traditional methods, with one fermentation tank yielding the equivalent of thousands of acres of stevia plants [10]. Group 3: Industry Context and Policy Support - The synthetic biology sector in China has seen increased investment and policy support, with total annual investments ranging from 50 to 100 billion RMB from 2018 to 2020, and a significant surge in 2021 [14][15]. - Chengdu, where Yingjiaohesheng is located, has strategically positioned itself as a hub for the biopharmaceutical industry, with a total scale of 350 billion RMB in the health industry as of 2023 [19][20]. - The city has implemented policies to foster the development of synthetic biology, aiming to create a robust ecosystem that integrates innovation, capital, and industry [21][22].

Core Viewpoint - The article highlights the investment in Sichuan Yingjia Hesheng Technology Co., Ltd., a major producer of steviol glycosides, emphasizing its role in the synthetic biology sector and its potential for growth in various markets, particularly in the U.S. and Southeast Asia [2][5]. Company Overview - Yingjia Hesheng, established in 2015, focuses on using synthetic biology to manufacture natural products, with applications in pharmaceuticals, health care, and food and beverage industries [4]. - It is the largest supplier of steviol glycosides in China and one of only three companies globally to receive GRAS certification for its rare steviol glycoside, Rebaudioside I [3][5]. Market Position - Since 2019, Yingjia Hesheng has successfully entered the U.S. market and is part of the supply chains of several international food and beverage companies, with increasing sales in the UK and Southeast Asia [5]. - The company is also planning to expand into emerging markets such as Japan and South Korea [5]. Product Line - In addition to steviol glycosides, Yingjia Hesheng's product portfolio includes Coenzyme Q10, new types of steviol glycosides, β-Nicotinamide Mononucleotide (NMN), and vanillin, covering multiple sectors including pharmaceuticals and health supplements [5]. Industry Development - Chengdu is positioning itself as a significant hub for synthetic biology and biomanufacturing, with over 300 biopharmaceutical projects introduced by the end of 2024, and a total industry scale exceeding 350 billion yuan [9][10]. - The local government has implemented policies to support the development of synthetic biology, recognizing its potential to replace traditional chemical processes and enhance the local economy [10][11].

Core Viewpoint - Chengdu has proactively laid out the synthetic biology sector, with Yingjia Hesheng being a prominent player in the stevia glycosides market, utilizing synthetic biology technology for production [1][4][8]. Company Overview - Yingjia Hesheng Technology Co., Ltd. is a leading supplier of stevia glycosides in China, established in 2015, focusing on synthetic biology to manufacture natural products for various industries including pharmaceuticals and food [2][4][6]. - The company has developed a rare stevia glycoside, Rebaudioside I (Rebl), which has received GRAS (Generally Recognized As Safe) certification from the FDA, making it the only Chinese company among three globally to achieve this [6][7]. Market Position - China is the largest producer of stevia glycosides, and Yingjia Hesheng is one of the top suppliers, successfully entering the U.S. market since 2019 and expanding sales in regions like the UK and Southeast Asia [4][7]. - The company’s product line includes coenzyme Q10, new stevia glycosides, NMN, and vanillin, with a focus on health-conscious consumers [7]. Technology and Production - Yingjia Hesheng employs synthetic biology for stevia glycoside production, which offers significant cost advantages over traditional extraction methods that require large-scale cultivation of stevia plants [9]. - The synthetic biology approach allows for higher yields and lower waste, with one fermentation tank producing as much stevia glycoside as thousands of acres of stevia plants [9]. Industry Development - The synthetic biology sector in China has seen increased investment and policy support, with a notable surge in financing in 2021, indicating a growing interest and potential in this field [12][13]. - Chengdu's government has prioritized the development of synthetic biology, integrating it into broader economic plans and providing a conducive environment for companies like Yingjia Hesheng [17][18]. Future Prospects - Yingjia Hesheng aims to increase its annual output value from 200 million yuan to 1 billion yuan within three years, supported by the establishment of a new production facility by 2025 [9]. - The collaboration between synthetic biology and traditional pharmaceutical industries presents vast opportunities for innovation and cost reduction in drug production [18].